Thus, the TXNIP/thioredoxin axis is a promising therapeutic target for reducing oxidative damage in MetS since its overexpression is linked to poor glucose metabolism and increased apoptosis in pancreatic β-cells [13,14]. Here, TXN is linked to metabolic syndrome.